Blockade by anti-CD47 mAb has been shown to reduce tumor burden by effects linked to increased phagocytosis of tumor cells35, although a recent study has shown that anti-tumor effects of anti-CD47 mAb are dependent on CD8 T cells and DC activation3. This evidence concerns the gene CD47 and neoplasm.